Evofem Biosciences, Inc. (EVFM)
| Previous Close | 0.0099 |
| Open | 0.0091 |
| Bid | 0.0091 x 1100 |
| Ask | 0.0097 x 1800 |
| Day's Range | 0.0091 - 0.0091 |
| 52 Week Range | 0.0060 - 0.2260 |
| Volume | |
| Avg. Volume | 1,228,206 |
| Market Cap | 912,993 |
| Beta (5Y Monthly) | -0.69 |
| PE Ratio (TTM) | 0.00 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
MOUNTAIN VIEW, Calif. & SAN DIEGO, September 09, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating health innovations, and women’s health pioneer, Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem") today announced they have entered into the Second Amendment to the Amended and Restated Agreement and Plan of Merger (the "Second Amendment"), under which Aditxt intends to acquire Evofem.
- Business Wire
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
MOUNTAIN VIEW, Calif., August 29, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024.
- PR Newswire
Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution
As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is raising awareness of the potential impact these medications may have on the effectiveness of oral contraceptives. With an increasing number of women turning to GLP-1 medications for weight management and glycemic control, the need for reliable non-oral contraceptive options has never been more acute.
